Journey Medical Corp (NASDAQ: DERM) on Monday, plunged -13.78% from the previous trading day, before settling in for the closing price of $6.17. Within the past 52 weeks, DERM’s price has moved between $2.85 and $8.11.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 23.37%. The company achieved an average annual earnings per share of -408.57%. With a float of $10.04 million, this company’s outstanding shares have now reached $13.32 million.
Let’s determine the extent of company efficiency that accounts for 58 employees. In terms of profitability, gross margin is 66.79%, operating margin of 2.73%, and the pretax margin is 1.37%.
Journey Medical Corp (DERM) Breakdown of a Key Holders of the stock
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Journey Medical Corp is 51.56%, while institutional ownership is 11.48%. The most recent insider transaction that took place on Aug 01 ’24, was worth 51,002. In this transaction CFO of this company sold 9,324 shares at a rate of $5.47, taking the stock ownership to the 47,331 shares. Before that another transaction happened on Jul 23 ’24, when Company’s CFO sold 4,055 for $5.40, making the entire transaction worth $21,897. This insider now owns 56,655 shares in total.
Journey Medical Corp (DERM) Recent Fiscal highlights
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported 0.8 earnings per share (EPS) for the period topping the consensus outlook (set at -0.15) by 0.95. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.32 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -408.57% per share during the next fiscal year.
Journey Medical Corp (NASDAQ: DERM) Trading Performance Indicators
Journey Medical Corp (DERM) is currently performing well based on its current performance indicators. A quick ratio of 1.08 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.01, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.21 in one year’s time.
Technical Analysis of Journey Medical Corp (DERM)
Looking closely at Journey Medical Corp (NASDAQ: DERM), its last 5-days average volume was 0.29 million, which is a jump from its year-to-date volume of 0.12 million. As of the previous 9 days, the stock’s Stochastic %D was 48.96%. Additionally, its Average True Range was 0.51.
During the past 100 days, Journey Medical Corp’s (DERM) raw stochastic average was set at 41.42%, which indicates a significant increase from 18.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 100.40% in the past 14 days, which was higher than the 72.18% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.53, while its 200-day Moving Average is $4.68. However, in the short run, Journey Medical Corp’s stock first resistance to watch stands at $6.10. Second resistance stands at $6.89. The third major resistance level sits at $7.44. If the price goes on to break the first support level at $4.77, it is likely to go to the next support level at $4.22. Now, if the price goes above the second support level, the third support stands at $3.43.
Journey Medical Corp (NASDAQ: DERM) Key Stats
Market capitalization of the company is 118.33 million based on 20,727K outstanding shares. Right now, sales total 79,180 K and income totals -3,850 K. The company made 14,860 K in profit during its latest quarter, and -3,360 K in sales during its previous quarter.
